abaloparatide vs romosozumab
Side-by-side comparison of abaloparatide and romosozumab Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tymlos
Evenity
Tymlos is a medicine to treat osteoporosis. It helps make your bones stronger and less likely to break.
Evenity is a medicine to treat osteoporosis in women after menopause who are at high risk for bone fracture. It can help make your bones stronger.
Tymlos treats osteoporosis in women after menopause and in men. It is for people who have a high chance of breaking a bone. This includes those who have already had a bone break due to osteoporosis or have other risk factors. It can also be used if other osteoporosis treatments did not work or could not be tolerated.
Evenity treats osteoporosis in women after menopause. It is for women at high risk of breaking a bone due to osteoporosis. This includes women who have already had a fracture or have multiple risk factors for fracture. It can also be used if other osteoporosis treatments did not work or could not be tolerated.
Tymlos is similar to a natural hormone in your body. It helps your body build new bone. This makes your bones stronger and less likely to break.
Evenity works by blocking a protein called sclerostin. Sclerostin slows down new bone formation. By blocking sclerostin, Evenity helps your body build new bone and increase bone strength.
- • High calcium in your urine
- • Feeling dizzy
- • Feeling sick to your stomach
- • Headache
- • Feeling your heart beat fast or irregularly
- • Joint pain
- • Headache
- Headache 4,180
- Feeling sick to your stomach 3,222
- Feeling dizzy 3,122
- Feeling tired 2,742
- Increased heart rate 2,139
No adverse event reports.
Tymlos may increase the risk of bone cancer (osteosarcoma). You should not take this medicine if you have certain conditions that increase this risk. These include Paget's disease, bone cancer, radiation treatment to your bones, or certain hereditary disorders. If you have symptoms of feeling dizzy, palpitations, tachycardia, or nausea, you should sit or lie down.
Evenity may increase your risk of heart attack, stroke, and death from heart problems. You should not start Evenity if you have had a heart attack or stroke in the past year. Your doctor will consider if the benefits of Evenity outweigh these risks if you have other heart risk factors. If you have a heart attack or stroke while taking Evenity, stop taking it.
Tymlos is not for women who could get pregnant. It is not known if Tymlos can harm an unborn baby or pass into breast milk.
Evenity is not for women who could become pregnant. Animal studies showed harm to the baby when Evenity was given to pregnant animals. It is also unknown if Evenity passes into breast milk.
How to Read This abaloparatide vs romosozumab Comparison
abaloparatide is classified in the PTHrP Analog drug class, while romosozumab sits within the Sclerostin Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, abaloparatide has 15,405 submissions while romosozumab has 0. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between abaloparatide and romosozumab — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.